Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery

Cost-effectiveness of screening forHLA-A*31:01prior to initiation of carbamazepine in epilepsy

(2015) Catrin O. Plumpton et al.   EPILEPSIA

Comprehensive Survival Analysis of a Cohort of Patients with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

(2013) Peggy Sekula et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

An agenda for UK clinical pharmacology: Provision of medicines information: the example of the British National Formulary

(2012) Martin Kendall et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review

(2012) V L Yip et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Patients' preferences for treatment outcomes of add-on antiepileptic drugs: A conjoint analysis

(2012) Ranjani Manjunath et al.   EPILEPSY & BEHAVIOR

Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations

(2011) Joanna Coast et al.   HEALTH ECONOMICS

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences

(2011) Katherine Payne et al.   VALUE IN HEALTH

Discrete choice experiments in health economics: a review of the literature

(2010) Esther W. de Bekker-Grob et al.   HEALTH ECONOMICS

CNS Adverse Events Associated with Antiepileptic Drugs

(2008) Gina M Kennedy et al.   CNS DRUGS

Predictive Validity of a Medication Adherence Measure in an Outpatient Setting

(2008) Donald E. Morisky et al.   Journal of Clinical Hypertension